scholarly journals Soluble CD163 as a Potential Biomarker in Systemic Sclerosis

2018 ◽  
Vol 2018 ◽  
pp. 1-5 ◽  
Author(s):  
Camelia Frantz ◽  
Sonia Pezet ◽  
Jerome Avouac ◽  
Yannick Allanore
Keyword(s):  
Systemic Sclerosis ◽  
Clinical Laboratory ◽  
Control Group ◽  
Signaling System ◽  
Serum Samples ◽  
Cross Sectional ◽  
Potential Biomarker ◽  
Significant Difference ◽  
Urine And Serum ◽  
Age And Sex

Objective. To evaluate the performance of serum and urinary sCD163 concentrations as possible biomarker in systemic sclerosis (SSc). Methods. Urine and serum samples were obtained from SSc patients and age- and sex-matched controls. Serum and urinary sCD163 concentrations were measured by commercially available ELISA kit. SSc patients were assessed following international guidelines. Cross-sectional analyses were performed. Results. Two hundred and three SSc patients were included. The control group consisted of 47 age- and sex-matched patients having noninflammatory diseases, mainly osteoporosis. Serum sCD163 levels were significantly higher in SSc patients compared with controls (mean ± SD: 529 ± 251 versus 385 ± 153 ng/mL; p<0.001). Urinary sCD163 concentrations were higher in SSc patients than controls, but this did not reach significance (236 ± 498 versus 176 ± 173 ng/mg uCr; p=0.580). The sCD163 concentrations were not associated with clinical, laboratory, and instrumental characteristics of SSc patients. Conclusion. To our knowledge, this is the first evaluation of both serum and urinary sCD163 levels in SSc. Our results show a significant difference for sera values that should be prioritized for further studies as compared to urinary measurements. Our results further support that the M2 macrophages/CD163 signaling system may play a role in the pathogenesis of SSc, although we could not identify a subset of SSc patients with higher concentrations.

scholarly journals Serum malondialdehyde (MDA) level as a potential biomarker of cancer progression for patients with bladder cancer

2020 ◽  
Vol 58 (3) ◽  
pp. 146-152
Author(s):  
Zahid Lepara ◽  
Orhan Lepara ◽  
Almir Fajkić ◽  
Damir Rebić ◽  
Jasmin Alić ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Bladder Cancer ◽  
Cancer Progression ◽  
Cross Sectional Study ◽  
Control Group ◽  
Cross Sectional ◽  
Potential Biomarker ◽  
Significant Difference ◽  
Progression Risk ◽  
T1 And T2

AbstractIntroduction. Bladder cancer is the most common malignancy involving the urinary system. Recent research tends to emphasize the role of oxidative stress products in the carcinogenesis of bladder cancer. The level of oxidative stress can be measured by assessing the MDA levels. This study aimed to evaluate serum MDA levels in patients with bladder cancer, as well as to determine its potential role as a biomarker in the diagnosis of the disease and progression risk considerations.Methods. The study was designed as a cross-sectional study and included 90 patients, divided into three groups with 30 patients each: Ta, T1and T2–T4 group, based on histopathological findings after transurethral resection of the tumor. The control group included 30 healthy volunteers. MDA level was determined using the spectrophotometric method.Results. Serum MDA level in patients with bladder cancer [0.86 (0.78–1.05) μmol/L] was significantly higher than the serum MDA level in control group [0.70 (0.69–0.72) μmol/L] (p < 0.001). Serum MDA level in Ta group [0.73 (0.70–1.05) μmol/L], T1 group [0.85 (0.80–1.12) μmol/L] and in T2–T4 group [0.91 (0.84–1.04) μmol/L] was significantly higher than the serum MDA level in control group [0.70 (0.69–0.72) μmol/L] (p < 0.01). MDA level in T1 and T2–T4 group was significantly higher than the MDA level in Ta group (p < 0.01). No significant difference was observed in MDA level between T1 and T2–T4 group (p = NS). A statistically significant positive correlation was found between tumor size and serum MDA level in patients with bladder cancer (rho = 0.254 p < 0.01).Conclusions. The results of the present study suggest that MDA serum level might play a significant role as a biomarker in the diagnosis of bladder cancer, as well as in the monitoring of its progression.

scholarly journals Fascioliasis and COVID-19: A Case-Control Study in Iran

2021 ◽  
Author(s):  
Fatemeh Balazadeh ◽  
Mohammad Zibaei ◽  
Aliehsan Heidari ◽  
Hadis Rastad ◽  
Farzaneh Firoozeh
Keyword(s):  
Immune Responses ◽  
Fasciola Hepatica ◽  
Cross Sectional Study ◽  
Control Group ◽  
Serum Samples ◽  
Cross Sectional ◽  
Significant Difference ◽  
Healthy Control ◽  
And Gender ◽  
And Control

Abstract Background: Human Fascioliasis is a zoonotic infection caused by the adult stage of Fasciola species. Fasciola hepatica is a parasite that, following living in its vertebrate host, reduces the host's inflammatory immune responses to infectious diseases, including COVID-19. Therefore, because of the completely unproven and limited data on this issue, we decided to evaluate the prevalence of antibodies against this parasite in patients admitted to the hospital due to relatively severe symptoms of COVID-19.Methods: This cross-sectional study was conducted on the serum samples of 182 patients with COVID-19 disease who were diagnosed by PCR test and 210 healthy subjects in Alborz Province, Iran between March and June 2020. Anti-Fasciola antibodies status was determined in all serum samples, using ELISA technique. A self-developed questionnaire was used to measure demographic information.Results: The frequency of Fasciola infection was found to be significantly higher in COVID-19 patients as compared to healthy control (n = 4, 2.2%, n = 9, 4.3%; respectively) (P = 0.041). There was no significant difference between COVID-19 patients and control group in age, education, and gender (P > 0.05).Conclusions: This study indicates that a significant association between Fasciola hepatica seropositivity and COVID-19 disease. Our finding suggests that Fasciola infection may be able to lead to decreased immune responses, thereby reducing the severity and symptoms of COVID-19 disease.

scholarly journals Investigation of Possible Role of Chlamydia in Pseudoexfoliation Syndrome

2021 ◽  
Vol 14 (5) ◽  
Author(s):  
Serpil Gonca ◽  
Mehmet Sami Serin ◽  
Ayca Yilmaz ◽  
Ozgun Oktay ◽  
Ayse Serin ◽  
...  
Keyword(s):  
Systemic Disease ◽  
Tertiary Hospital ◽  
Cross Sectional Study ◽  
Pseudoexfoliation Syndrome ◽  
Unknown Etiology ◽  
Control Group ◽  
Serum Samples ◽  
Cross Sectional ◽  
Significant Difference

Background: Pseudoexfoliation syndrome (PES) is a systemic disease characterized by the aggregation of fibrillar extracellular material in intraocular and extraocular tissues with unknown etiology. Clarifying the etiopathogenesis of PES would be important for public health. Objectives: We aimed to investigate the possible role of Chlamydia in the etiology of PES. Methods: This cross-sectional study was carried out in the ophthalmology clinic of a tertiary hospital. The study included two groups, including the patient group (PES patients with nuclear cataracts) and the control group (patients with nuclear cataracts). Patients with other ophthalmic problems and systemic diseases were excluded. Blood samples and conjunctival swabs taken from 49 patients and 42 controls were used in the study. Anti-Chlamydia trachomatis IgG and IgM, anti-C. pneumoniae IgG and IgM, Interleukin (IL)-6, and IL-20 were studied in the serum samples. The PCR study was performed with conjunctival swab samples and sequence analysis of PCR-positive samples was performed. Results: According to the results of the study, there was no statistically significant difference between the groups in terms of anti-C. trachmatis IgG, anti-C. trachmatis IgM, anti-C. pneumoniae IgM, IL-6, and PCR results. There was a statistically significant difference between patient and control groups in terms of anti-C. pneumoniae IgG and IL-20 levels. The DNA sequencing of all PCR products was found to be compatible with C. pneumoniae. Conclusions: It seems that C. pneumoniae might have an important role in the etiology and development of PES. However, further studies in larger groups are needed to clarify these results.

scholarly journals PD-1 Is an Immune-Inflammatory Potential Biomarker in Cerebrospinal Fluid and Serum of Intractable Epilepsy

2021 ◽  
Vol 2021 ◽  
pp. 1-10
Author(s):  
Hong Tang ◽  
Xuefeng Wang
Keyword(s):  
Cerebrospinal Fluid ◽  
Status Epilepticus ◽  
Partial Seizure ◽  
Flow Cytometric Analysis ◽  
Intractable Epilepsy ◽  
Inflammatory Factors ◽  
Control Group ◽  
Serum Samples ◽  
Potential Biomarker ◽  
Significant Difference

Purpose. Previous studies have demonstrated that immune and inflammatory factors play an important role in recurrent seizures. The PD-1-PD-L pathway plays a central and peripheral immunosuppressive role by regulating multiple signaling pathways during the inflammatory and immunologic processes. This study is aimed at assessing PD-1 levels in cerebrospinal fluid (CSF) and serum samples from patients with intractable epilepsy. Methods. PD-1 levels were assessed in CSF and serum samples from 67 patients with intractable epilepsy (41 and 26 individuals with partial seizure and intractable status epilepticus, respectively) and 25 healthy controls, using flow cytometric analysis and sandwich enzyme-linked immunosorbent assays (ELISA). Results. Serum-PD-1+CD4+CD25high Treg levels in the experimental groups and the control group were 10.26 ± 2.53 (PS group), 35.95 ± 27.51 (ISE group), and 4.69 ± 2.44 (control group). In addition, CSF-PD-1 level in patients with epilepsy was higher than that in the control group ( 50.45 ± 29.56 versus 19.37 ± 4.51 ), indicating a statistically significant difference ( P < 0.05 ). Interestingly, serum- and CSF-PD-1 levels in individuals with epilepsy were not affected by antiepileptic drug and treatment course, but by epilepsy onset level. Of note, the increase of CSF- and serum-PD-1 levels was more pronounced in subjects with intractable status epilepticus than those with partial seizure. Conclusion. Serum- and CSF-PD-1 levels constitute a potential clinical diagnostic biomarker for intractable epilepsy and could also be used for differential diagnosis.

Clinical-Reported Outcomes Of Deferoxamine Versus Deferasirox In The Treatment Of Homozygous BetaThalassemia

2018 ◽  
Vol 9 (SPL1) ◽  
Author(s):  
Zeina A Munim Al-Thanoon ◽  
Zeina A Munim Al-Thanoon ◽  
Mustafa Basil ◽  
Nasih A Al-Kazzaz
Keyword(s):  
Serum Ferritin ◽  
Iron Chelation ◽  
Iron Chelator ◽  
Beta Thalassemia ◽  
Control Group ◽  
Current Standard ◽  
Cross Sectional ◽  
Significant Difference ◽  
Multiple Blood ◽  
Group 2

Iron chelation therapy with deferoxamine (DFO),the current standard for the treatment of iron overload in patients with betathalassemia,requires regular subcutaneous or intravenous infusions. This can lead to reduced quality of life and poor adherence,resulting in increased morbidity and mortality in iron-overloaded patients with beta-thalassemia. Deferasirox (DFX) is an orally administered iron chelator that has been approved for use in many countries. The requirement of an effective,well tolerated iron chelator with a less demanding mode of administration has led to the development of deferasirox. The present study was aimed to compare the satisfaction and compliance with deferoxamine versus deferasirox (Exjade®),a novel oral iron chelator in patients with transfusion - dependent beta- thalassemia. A cross-sectional,single-center investigation study was carried out in the Thalassemia Center of Ibn-Atheer Teaching Hospital in Nineveh province,Iraq. One hundred and eight thalassemic patients aged between 2- 20 years old having received multiple blood transfusions and a serum ferritin greater than 1500 ng/ml. Patients were randomised into two groups. Group 1 received deferoxamine at a dose of 20-50mg/kg/day and group 2 received deferasirox at the dose of 10-30 mg/kg/day. Another 56 apparently healthy volunteers were used as a control group. The assessment of chelation was done during the period between November 2013 and February 2014 by measurement of serum ferritin. Satisfaction and compliance was assessed by using a special questionnaire prepared by the researcher. Out of the 108 thalassemic patients enrolled there was no discontinuation in treatment with the two drugs under study. The serum ferritin did not change significantly in any of the chelation groups. In comparison with the patients who were treated with DFO,those receiving DFX reported a significantly higher rate of compliance and satisfaction (P < 0.05). However,no significant difference was observed between the two groups regarding their satisfaction (P > 0.05).Compliance with deferasirox (50 %) was more than that with deferoxamine (20 %). Satisfaction with deferoxamine was significantly lower than deferasirox (p= 0.00).

scholarly journals Reassessing the Role of the Active TGF-β1 as a Biomarker in Systemic Sclerosis: Association of Serum Levels with Clinical Manifestations

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Andréa Tavares Dantas ◽  
Sayonara Maria Calado Gonçalves ◽  
Anderson Rodrigues de Almeida ◽  
Rafaela Silva Guimarães Gonçalves ◽  
Maria Clara Pinheiro Duarte Sampaio ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Clinical Manifestations ◽  
Serum Levels ◽  
Vascular Involvement ◽  
Digital Ulcers ◽  
Serum Samples ◽  
Peripheral Blood Mononuclear ◽  
Pbmc Culture ◽  
Significant Difference ◽  
Skin Biopsies

Objective. To determine active TGF-β1 (aTGF-β1) levels in serum, skin, and peripheral blood mononuclear cell (PBMC) culture supernatants and to understand their associations with clinical parameters in systemic sclerosis (SSc) patients.Methods. We evaluated serum samples from 56 SSc patients and 24 healthy controls (HC). In 20 SSc patients, we quantified spontaneous or anti-CD3/CD28 stimulated production of aTGF-β1 by PBMC. The aTGF-β1 levels were measured by ELISA. Skin biopsies were obtained from 13 SSc patients and six HC, and TGFB1 expression was analyzed by RT-PCR.Results. TGF-β1 serum levels were significantly higher in SSc patients than in HC (p< 0.0001). Patients with increased TGF-β1 serum levels were more likely to have diffuse subset (p= 0.02), digital ulcers (p= 0.02), lung fibrosis (p< 0.0001), positive antitopoisomerase I (p= 0.03), and higher modified Rodnan score (p= 0.046). Most of our culture supernatant samples had undetectable levels of TGF-β1. No significant difference in TGFB1 expression was observed in the SSc skin compared with HC skin.Conclusion. Raised active TGF-β1 serum levels and their association with clinical manifestations in scleroderma patients suggest that this cytokine could be a marker of fibrotic and vascular involvement in SSc.

scholarly journals Blastocystis sp. Carriage and Irritable Bowel Syndrome: Is the Association Already Established?

Biology ◽  
2021 ◽  
Vol 10 (4) ◽  
pp. 340
Author(s):  
Fernando Salvador ◽  
Beatriz Lobo ◽  
Lidia Goterris ◽  
Carmen Alonso-Cotoner ◽  
Javier Santos ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Microscopic Examination ◽  
Parasitic Infection ◽  
Diagnostic Technique ◽  
Control Group ◽  
Cross Sectional ◽  
Significant Difference ◽  
Blastocystis Sp ◽  
Irritable Bowel ◽  
Asymptomatic Subjects

Background: The aim of the present study is to describe the occurrence of Blastocystis sp. detection among asymptomatic subjects and patients with irritable bowel syndrome in order to evaluate the potential association between irritable bowel syndrome and the parasitic infection. Methods: Cross-sectional study where adult patients with irritable bowel syndrome diagnosed according to Rome IV criteria were included. A control group was formed by asymptomatic subjects older than 18 years. Exclusion criteria were: immunosuppressive condition or having received any drug with demonstrated activity against Blastocystis sp. within the last 6 months before study inclusion. Epidemiological and clinical information was collected from all included participants. Two stool samples were obtained from all participants: one sample for microscopic examination and one sample for Blastocystis sp. PCR detection. Blastocystis sp. infection was defined by the positivity of any of the diagnostic techniques. Results: Seventy-two participants were included (36 asymptomatic subjects and 36 patients with irritable bowel syndrome). Thirty-five (48.6%) were men, and median age of participants was 34 (IQR 29–49) years. The overall rate of Blastocystis sp. carriage was 27.8% (20/72). The prevalence assessed through microscopic examination was 22.2% (16/72), while the prevalence measured by PCR was 15.3% (11/72). When comparing the presence of Blastocystis sp. between asymptomatic subjects and IBS patients, we did not find any statistically significant difference (36.1% vs. 19.4% respectively, p = 0.114). Conclusions: regarding the occurrence of Blastocystis sp., no differences were found between asymptomatic participants and patients with irritable bowel disease irrespective of the diagnostic technique performed.

Age-Dependent Three-Dimensional Evaluation of the Spheno-Occipital Synchondrosis Using Computed Tomography

2021 ◽  
Vol 15 (1) ◽  
Author(s):  
Arezoo Jahanbin ◽  
Shirin Dokht Shirazi ◽  
Elaheh Kamyabnezhad ◽  
Neda Eslami ◽  
Seyed Hosein Hoseini Zarch
Keyword(s):  
Developmental Stage ◽  
Three Dimensional ◽  
Cross Sectional ◽  
Old Patients ◽  
Significant Difference ◽  
Growth Center ◽  
Different Populations ◽  
Males And Females ◽  
Ossification Process ◽  
Age And Sex

Background: The spheno‐occipital synchondrosis (SOS) is an important growth center which plays an important role in cranial base development and can define the final relation of SOS with the upper and lower jaws. The morphology and fusion degree of SOS varies in different ages among different populations. Objectives: Thus, the aim of this study was to evaluate the age and sex dependence of ossification of the spheno-occipital synchondrosis in the Iranian population using CBCT. Methods: This cross-sectional retrospective study was performed on 517 CBCT images of 6- to 18-year-old patients in Mashhad, Iran. Patients with obvious pathology or fractures were excluded from the study. The SOS ossification was classified into four stages from 0 to 3. Two independent observers scored the images. The ossification stage of the SOS was classified according to the age and sex of the patients. Kruskal-Wallis and Kendall’s tau-b used for statistical analysis. Results: In this study, 517 samples of 260 females (50.3%) and 257 males (49.7%) with a mean age of 12.03 ± 3.74 years were examined. A significant difference did not exist between males and females regarding their stage of SOS ossification, although males were younger at the SOS transitional stages of 0 to 1, and 1 to 2 compared to females. Also, the SOS starts the ossification process at the age of 11 in females and 10.8 in males. Conclusions: The present study showed in the mean age of 16.81 ± 1.12 years, most subjects were in developmental stage 3. Due to the fact that in developmental stage 3 SOS closes, there were no passive maxillary growth after this time. In none of the SOS stages, females and males differed significantly in mean age (P > 0.05). The age of the onset of SOS closure in females was 11 years and in males it was about 10.8 years.

scholarly journals Anolunula in Fingernails among Patients Infected with HIV

2014 ◽  
Vol 2014 ◽  
pp. 1-6
Author(s):  
Pratik Gahalaut ◽  
Nitin Mishra ◽  
Sandhya Chauhan ◽  
Mir Mubashir Ali ◽  
Madhur Kant Rastogi ◽  
...  
Keyword(s):  
Hiv Infection ◽  
Cross Sectional Study ◽  
Negative Control ◽  
Hiv Positive ◽  
Control Group ◽  
Cross Sectional ◽  
Significant Difference ◽  
Stage 1 ◽  
And Control ◽  
Hiv Negative

Lunula is the white, half-moon shaped area seen in proximal ends of some nails. Though a few studies have described the nail changes that can occur in association with HIV infection, none of these paid much attention to lunula. Aims and Objectives. To study the lunula in fingernails among HIV infected patients. Materials and Methods. An observational, cross-sectional study to record presence of lunula in 168 HIV-positive patients and compare it with age and sex matched 168 healthy HIV-negative control. Anolunula (absence of lunula) in HIV-positive patients was correlated with CD4 counts, stages of HIV infection, time since patient was diagnosed as HIV-positive, and status of antiretroviral therapy. Results. Anolunula was present in significantly more fingernails in HIV-positive patients compared to HIV-negative controls. There was a highly significant difference for total anolunula (anolunula in all fingernails) in study and control group. Incidence of total anolunula was directly proportional to the stage of HIV infection, increasing progressively as the HIV infection advances from stage 1 to stage 4. Conclusion. Absence of lunula is related to not only HIV infection per se but also the stages of HIV infection.

Correlation of salivary neopterin and plasma fibrinogen levels in patients with chronic periodontitis and/or type 2 diabetes mellitus

Pteridines ◽  
2017 ◽  
Vol 28 (3-4) ◽  
pp. 177-183 ◽  
Author(s):  
Angel Fenol ◽  
V.R. Swetha ◽  
Sajitha Krishnan ◽  
Jayachandran Perayil ◽  
Rajesh Vyloppillil ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Chronic Periodontitis ◽  
Study Groups ◽  
Control Group ◽  
Diabetic Patients ◽  
Potential Biomarker ◽  
Whole Saliva ◽  
Nonsurgical Periodontal Therapy ◽  
Significant Difference

AbstractNeopterin is a novel predictor for coronary events especially in diabetic patients and also an indicator for the effectiveness of the periodontal treatment. In this study, we assessed whether salivary neopterin can be used as a potential biomarker in evaluating the risk of cardiovascular disease in type 2 diabetic patients with chronic periodontitis. Forty subjects between 25 and 75 years of age and who matched the criteria were selected and divided into four groups. Their periodontal status was evaluated. Stimulated whole saliva and blood were collected for analysis of salivary neopterin and fibrinogen and HbA1c levels, respectively. Nonsurgical periodontal therapy was carried out. Patients were recalled after 3 months, and the same procedure was repeated. A reduction in all the parameters was seen after treatment in all the four groups. Salivary neopterin levels showed significant difference (p<0.001) in the values between the study groups and the control group before treatment. After 3 months of treatment, salivary neopterin levels showed a statistical significant reduction (p<0.001) in all the study groups. Neopterin could serve as an effective tool to assess the inflammatory process related to periodontitis and diabetes mellitus and also predict future cardiovascular events in diabetic patients.

Sign in / Sign up

Export Citation Format

Share Document